INVESTORS

Investor Relations

Recent News
May 15, 2019

- SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1st - - Sierra to hold Analyst & Investor Event at 6:00 am CT on June 3rd...

May 8, 2019

Momelotinib regulatory pathway clarity anticipated in Q2 2019 - - SRA737 Phase 1/2 preliminary clinical data anticipated at the 2019 ASCO Annual Meeting - VANCOUVER, May 8, 2019 /CNW/ - Sierra...

May 6, 2019

Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...

View all news releases

Events and Webcasts
Monday, June 3, 2019
6:00am - 7:00am CDT

Location: History event room, Marriot Marquis Hotel, 2121 S Prairie Ave, Chicago, Illinois RSVP to attend in-person:...

View all events and webcasts

Annual Meeting of Stockholders

Date: Tuesday, June 11, 2019
Time: 10:00 am PT
Location: Four Seasons Hotel, 791 West Georgia Street, Vancouver, British Columbia V6C 2T4

Materials:

Investor Enquiries

James Smith, Vice President Corporate Affairs
investors@sierraoncology.com

Sign up for investor alerts